Diane Gbesemete

Diane Gbesemete

Auto-generated profile, based on publicly available information

Diane Gbesemete

Controlled Human Infection Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton , Southampton

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2021 in Journal of Infection
Verified
Journal Article
Closed access
HCH. Chappell
H. Chappell
RPR. Patel
R. Patel
CDC. Driessens
C. Driessens
ATAlexander Tarr
Alexander Tarr
WIW.L. Irving
W.L. Irving
HGH. de Graaf
H. de Graaf

10 February 2022 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
CBCaroline Barker
Caroline Barker
KCKatharine Collet
Katharine Collet
DGDiane Gbesemete
Diane Gbesemete
MPMaria Piggin
Maria Piggin
DWDaniella Watson
Daniella Watson
HWHelen Ward
Helen Ward
Background: Human challenge studies involve the deliberate exposure of healthy volunteers to an infectious micro-organism in a highly controlled and monitored way. They are used to understand infectious diseases and have contributed to the development of vaccines. In early 2020, the UK started exploring the feasibility of establishing a human challenge study with SARS-CoV-2. Given the significant public interest and the complexity of the potential risks and benefits, it is vital that public views are considered in the design and approval of any such study and that investigators and ethics boards remain accountable to the public. Methods: Mixed methods study comprising online surveys conducted with 2,441 UK adults and in-depth virtual focus groups with 57 UK adults during October 2020 to explore the public’s attitudes to a human challenge study with SARS-CoV-2 taking place in the UK. Results: There was overall agreement across the surveys and focus groups that a human challenge study with SARS-CoV-2 should take place in the UK. Transparency of information, trust and the necessity to provide clear information on potential risks to study human challenge study participants were important. The perceived risks of taking part included the risk of developing long-term effects from COVID, impact on personal commitments and mental health implications of isolation. There were a number of practical realities to taking part that would influence a volunteer’s ability to participate (e.g. Wi-Fi, access to exercise, outside space and work, family and pet commitments). Conclusions: The results identified practical considerations for teams designing human challenge studies. Recommendations were grouped: 1) messaging to potential study participants, 2) review of the protocol and organisation of the study, and 3) more broadly, making the study more inclusive and relevant. This study highlights the value of public consultation in research, particularly in fields attracting public interest and scrutiny.

1 December 2025 in The Lancet Microbe
Verified
Journal Article
Open access
DGDiane Gbesemete
Diane Gbesemete
MRMaheshi N Ramasamy
Maheshi N Ramasamy
MIMuktar Ibrahim
Muktar Ibrahim
AHAlison R Hill
Alison R Hill
LRLucy Raud
Lucy Raud
RRRobert C Read
Robert C Read
Pertussis is a severe respiratory disease caused by Bordetella pertussis. Although vaccines prevent disease for a limited duration, they do not prevent infection and transmission. We aimed to assess the safety and efficacy of BPZE1 at preventing or substantially reducing colonisation by virulent B pertussis using a robust controlled human infection model. This randomised, placebo-controlled, phase 2b trial was conducted at University Hospital Southampton and University of Oxford in the UK. Eligible participants were healthy adults aged 18-50 years, who complied with the protocol, refrained from smoking and nasal sprays, and were fully vaccinated against SARS-CoV-2. Exclusion criteria were pertussis vaccination or illness (20 International Units [IU]/mL) or anti-pertactin serum IgG (>30 IU/mL) concentrations, and a positive SARS-CoV-2 test. Participants were randomly assigned (1:1), using permuted blocks with a block size of four, to receive an intranasal dose of 109 colony-forming units (CFU) of BPZE1 or placebo (lyophilised buffer) and were challenged 60-120 days later with 105 CFU virulent B pertussis. Masked staff administered the study vaccine. Nasal mucosal secretion and blood samples were collected. The primary outcome was negative B pertussis cultures of nasal washes at days 9, 11, and 14 after virulent challenge in the modified intention-to-treat (mITT; defined as all participants randomly assigned to treatment who were vaccinated, challenged, and had at least one culture result at day 9, 11, or 14 post-challenge) and per protocol adequate inoculum populations (defined as all participants in the mITT population who received a challenge inoculum equal to or higher than the target (≥0·5 × 105 CFU; sensitivity analysis). This trial is registered with ClinicalTrials.gov, NCT05461131. Between June 23, 2022, and Oct 26, 2023, 141 participants were assessed for eligibility, of whom 88 were ineligible and 53 were randomly assigned (26 to the BPZE1 group and 27 to the placebo group). 26 (49%) participants were male and 27 (51%) were female, with a mean age of 30·42 years (SD 8·49). Participants self-identified as White (42 [79%]), Black (six [11%]), or Asian (five [9%]). Five (9%) participants did not receive virulent challenge and two (4%) were lost to follow-up before virulent challenge. 46 (87%) participants received virulent challenge at 60-120 days (24 in the BPZE1 group vs 22 in the placebo group). One in the BPZE1 group withdrew consent and one in the placebo group was not evaluable due to COVID-19. 44 (83%) completed the challenge trial unit stay (23 [88%] vs 21 [78%]). 24 (92%) participants in the BPZE1 group and 21 (78%) in the placebo group were included in the mITT population. In the mITT population, the number of participants with no detectable colonisation on days 9, 11, and 14 post-challenge was higher in the BPZE1 group (14 [58%; 95% CI 39-76] of 24 vs seven [33%; 17-55] of 21 in the placebo group; p=0·091). Four (17%) in the BPZE1 group and five (24%) in the placebo group received a lower challenge dose than the target. In the per protocol adequate inoculum population, 12 (60%; 39-78) of 20 in the BPZE1 group and four (25%; 10-50) of 16 in the placebo group had no detectable colonisation by B pertussis B1917 on days 9, 11, and 14 post-challenge (p=0·033). Most participants reported at least one solicited adverse event during the 7 days after vaccination (22 [85%] of 26 in the BPZE1 group vs 22 [81%] of 27 in the placebo group), which were mostly mild (grade 1) in severity. Unsolicited adverse events were reported in similar frequency in the BPZE1 and placebo groups during the 28 days after vaccination (seven [27%] of 26 vs nine [33%] of 27). No serious adverse events or discontinuations due to adverse events were reported during the trial. Intranasal BPZE1 vaccination prevented or substantially reduced infection after challenge with virulent B pertussis and is an attractive vaccine candidate. Given the favourable safety profile, large phase 3 trials are warranted to confirm these initial findings. ILiAD Biotechnologies.

1 April 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
DGDiane Gbesemete
Diane Gbesemete
JLJay Robert Laver
Jay Robert Laver
HGHans de Graaf
Hans de Graaf
MIMuktar Ibrahim
Muktar Ibrahim
AVAndrew Vaughan
Andrew Vaughan
RRRobert Charles Read
Robert Charles Read
Introduction: Neisseria lactamicais a commensal organism found in the human nasopharynx and is closely related to the pathogenN. meningitidis(meningococcus). Carriage ofN. lactamicais associated with reduced meningococcal carriage and disease. We summarise an ethically approved protocol for an experimental human challenge study using a genetically modified strain ofN. lactamicathat expresses the meningococcal antigen NadA. We aim to develop a model to study the role of specific bacterial antigens in nasopharyngeal carriage and immunity, to evaluate vaccines for their efficacy in preventing colonisation and to provide a proof of principle for the development of bacterial medicines.Methods and analysis: Healthy adult volunteers aged 18–45 years will receive an intranasal inoculation of either the NadA containing strain ofN. lactamicaor a genetically modified, but wild-type equivalent control strain. These challenge volunteers will be admitted for 4.5 days observation following inoculation and will then be discharged with strict infection control rules. Bedroom contacts of the challenge volunteers will also be enrolled as contact volunteers. Safety, colonisation, shedding, transmission and immunogenicity will be assessed over 90 days after which carriage will be terminated with antibiotic eradication therapy.Ethics and dissemination: This study has been approved by the Department for Environment, Food and Rural Affairs and South Central Oxford A Research Ethics Committee (reference: 18/SC/0133). Findings will be published in peer-reviewed open-access journals as soon as possible.Trial registration number: NCT03630250; Pre-results.

23 March 2026 in The Lancet Microbe
Verified
Journal Article
Open access
HGHans de Graaf
Hans de Graaf
DGDiane F Gbesemete
Diane F Gbesemete
AHAlison R Hill
Alison R Hill
JFJaneri Fröberg
Janeri Fröberg
MIMuktar M Ibrahim
Muktar M Ibrahim
RRRobert C Read
Robert C Read
Cyclical epidemics of pertussis, also known as whooping cough, continue to occur despite vaccination, because current vaccines fail to suppress colonisation by, and transmission of, the causative agent Bordetella pertussis. We aimed to show the safety of B pertussis controlled human infection delivered in an outpatient setting, as well as identify immunological correlates of protection against B pertussis colonisation, to guide the future development of pertussis vaccines. This open-label, phase 1, controlled human infection study was conducted at University Hospital Southampton, Southampton, UK. Healthy volunteers aged 18-55 years who had received a whole-cell pertussis vaccine in childhood were inoculated intranasally with 105 colony-forming units of wild-type B pertussis strain B1917. Volunteers were monitored as outpatients for 28 days to assess safety, colonisation, and B pertussis-specific immunological parameters. Individuals who shared a bedroom with inoculated volunteers were enrolled to measure transmission to close contacts. After approximately 90 days, volunteers who agreed to participate in a rechallenge phase of the study were re-inoculated with the same dose of B pertussis. Volunteers received azithromycin 14 days after each inoculation. The primary objective was to assess the safety of delivering this controlled human infection model on an outpatient basis; safety endpoints were the occurrence of possible or confirmed pertussis and unsolicited or serious adverse events. Secondary objectives were the assessment of immunological biomarkers of protection from colonisation and the assessment of transmission from volunteers to close contacts. All volunteers who received the inoculum were included in the safety analysis, and all participants who completed follow-up to day 14 were included in the per-protocol population for colonisation and immunological analysis. This trial is registered at ClinicalTrials.gov, NCT03751514, and is ongoing. Between Aug 29, 2019 and March 6, 2023, 77 volunteers were screened and 51 were enrolled and inoculated, of whom 50 completed follow-up to day 14 post-inoculation. 20 (40%) of these 50 volunteers became colonised with B pertussis. One volunteer developed symptoms suggestive of possible pertussis after initial inoculation; this volunteer tested negative for B pertussis throughout the study and all symptoms resolved within 4 days. Adverse events were mostly mild to moderate, with no significant increase in the reporting of any individual symptom by colonised volunteers. All unsolicited adverse events were assessed as either unlikely to be related or unrelated to B pertussis infection, with no increase in the frequency of these events seen in colonised volunteers. There were no serious adverse events and no treatment-related deaths. Compared with those who became colonised with B pertussis, non-colonised volunteers had significantly higher pre-inoculation serum IgG antibody concentrations against several acellular pertussis vaccine antigens (pertussis toxin [p=0·028], pertactin [p=0·037], and filamentous haemagglutinin [p=0·024]); higher nasal (p=0·022) and serum (p=0·044) IgA antibody concentrations against whole B pertussis; higher serum IgA antibody concentrations specific to filamentous haemagglutinin (p=0·024); and higher peripheral T-helper (Th)-22-cell responses to pertussis toxin (p=0·0045) and filamentous haemagglutinin (p=0·029). After inoculation, only colonised volunteers showed seroconversion, IgA and IgG binding to B pertussis, and increases in B pertussis-specific IgG-secreting memory B-cell frequencies by day 28. Th17 responses to pertussis toxin were increased (p=0·039) and Th22 responses to filamentous haemagglutinin were decreased (p=0·014) in non-colonised volunteers. Of the 13 volunteers who became colonised after initial inoculation and were re-inoculated, only one (8%) became colonised after re-inoculation. Transmission from volunteers to 14 enrolled individuals with whom they shared a bedroom was not detected. Our findings suggest that controlled human infection with B pertussis in an outpatient setting is safe. Higher humoral and CD4+ T-cell responses with specificity to acellular pertussis vaccine antigens are associated with protection against colonisation by B pertussis after experimental challenge. This technique could enable the testing of potential novel vaccines or formulations for sustained protection against infection and transmission. EU Horizon 2020 (Innovative Medicines Initiative) and the National Institute for Health and Care Research Southampton Biomedical Research Centre.

26 December 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
DGD F Gbesemete
D F Gbesemete
FHF Haidara
F Haidara
JLJ R Laver
J R Laver
MIM Ibrahim
M Ibrahim
JMJ MacLennan
J MacLennan
RRR C Read
R C Read
Background: Carriage of Neisseria lactamica (Nlac), a harmless nasopharyngeal commensal, correlates inversely with carriage of Neisseria meningitidis (Nmen), a common cause of meningitis and sepsis outbreaks in sub-Saharan Africa. Nasally administered lyophilized Nlac (LyoNlac) might interrupt carriage and transmission of Nmen in sub-Saharan settings without requirement of a cold chain, but whether LyoNlac can establish colonization is undetermined. Methods: Healthy adult volunteers aged 18–45 years were inoculated intranasally with 104–107 colony forming units (CFU) of reconstituted, lyophilized Nlac strain Y92-1009 (LyoNlac) in 2 dose-ranging controlled human infection studies conducted in the United Kingdom and Mali. Safety was measured as a primary objective. Secondary objectives included the dose achieving ≥70% colonization rates for each setting, colonization kinetics, and serological responses. Both trials were registered with ClinicalTrials.gov (United Kingdom: NCT04135053, Mali: NCT04665791) and are complete. Results: Intranasal inoculation with LyoNlac was well tolerated with no significant safety concerns. In the United Kingdom, 105 CFU yielded 100% colonization (n = 10/10) while in Mali, 107 CFU achieved 65% colonization (n = 13/20). An increase in Nlac- and Nmen-specific IgG from pre-challenge to day 28 post-challenge was observed in colonized participants—median fold-change [interquartile range] United Kingdom: Nlac 2.24 [1.37–4.24], Nmen 1.39 [1.20–3.70] and Mali: Nlac 1.31 [1.04–1.94], Nmen 1.32 [0.99–1.73]. No significant seroconversion occurred in non-colonized participants. Conclusions: Intranasal inoculation with LyoNlac was safe and induced immunogenic nasopharyngeal colonization in healthy adults in the United Kingdom and Mali. Future clinical trials to determine whether LyoNlac reduces meningococcal carriage and transmission in the meningitis belt are warranted.